Article
Chemistry, Medicinal
Ariana M. Chao, Jena Shaw Tronieri, Anastassia Amaro, Thomas A. Wadden
Summary: Losing 5-10% or more of initial body weight can improve obesity-related comorbidities, but achieving and maintaining this weight loss level is challenging. The novel anti-obesity medication semaglutide, when used as an adjunct to a reduced-calorie diet and physical activity, helps patients achieve average weight losses of 9.6-17.4% of initial body weight at week 68 and improves cardiometabolic and psychosocial indices. Factors to consider for the selection and use of this medication include efficacy, safety, contraindications, adverse effects, comorbidity management, drug interactions, insurance coverage and cost, and patient preferences.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2022)
Review
Pharmacology & Pharmacy
Andrea Cignarella, Luca Busetto, Roberto Vettor
Summary: Pharmacological approaches to controlling body weight have shown limited success, but promising multiagonist strategies are under investigation. With careful patient selection and targeted compound development, improved outcomes for patients with obesity are anticipated in the near future.
PHARMACOLOGICAL RESEARCH
(2021)
Review
Endocrinology & Metabolism
Chelsi M. Webster, Neha Mittal, Emily J. Dhurandhar, Nikhil V. Dhurandhar
Summary: Obesity treatment requires negative energy balance. Medications can promote satiety or reduce hunger, but their efficacy and safety vary for individuals. Factors influencing weight-loss response to liraglutide include gender, diabetes status, baseline weight, and initial weight loss. Other factors like central effects, nausea, gastric emptying, and genotype may also impact treatment response. Identifying responders to liraglutide can assist healthcare providers and may provide insights for other obesity medications.
Review
Medicine, General & Internal
Marlene Chakhtoura, Rachelle Haber, Malak Ghezzawi, Caline Rhayem, Raya Tcheroyan, Christos S. Mantzoros
Summary: Obesity is a widespread health issue and medical weight management has seen significant advancements in recent years, leading to improved treatment options. Various medications have been approved for the management of obesity and there are promising novel drugs being researched.
Review
Endocrinology & Metabolism
Daniel J. Drucker
Summary: GLP1RA is an effective drug for the treatment of type 2 diabetes and has potential for obesity treatment. GLP-1 reduces food intake and body weight in both animals and humans, and its mechanisms of action have been extensively studied. GLP-1-based therapies may become important options for the treatment of obesity and its complications.
MOLECULAR METABOLISM
(2022)
Editorial Material
Clinical Neurology
Ronald R. Grunstein, Thomas A. Wadden, Julia L. Chapman, Atul Malhotra, Craig L. Phillips
Summary: Obesity is a chronic disease that affects over 670 million adults globally, leading to complications such as obstructive sleep apnea (OSA). Weight loss in patients with obesity-related OSA can effectively improve their condition, surpassing the benefits of device-based OSA therapies. Incretin-based pharmacotherapies have shown promising results in reducing weight and improving metabolic health, and ongoing trials are examining their efficacy in individuals with obesity-related OSA.
Article
Endocrinology & Metabolism
Samantha Hocking, Priya Sumithran
Summary: Obesity is increasing globally, driven by environmental factors and individual predisposition. Weight loss can improve health and reduce the risk of chronic diseases associated with obesity. However, obesity is a complex condition with different drivers and complications for each individual. While personalized prescribing of obesity medication has been successful in rare cases of monogenic obesity, it has been unsuccessful in polygenic obesity. Current evidence does not support targeted treatment based on individual characteristics, but with advances in technology and new treatments, precision medicine for obesity may become a reality in the future.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
(2023)
Article
Endocrinology & Metabolism
Cetin Sari, Richard L. Seip, Devika Umashanker
Summary: FDA approved anti-obesity medications may not be cost effective for patients struggling with pre-operative weight loss prior to bariatric surgery. Metformin, a biguanide, and Topiramate, a carbonic anhydrase inhibitor, have shown to be cost effective medications for weight loss in patients with type 2 diabetes or seizures, respectively, demonstrating success in achieving >8% total body weight loss prior to bariatric surgery for patients with a BMI >= 50 kg/m(2) who are unable to follow the prescribed nutritional plan due to dysregulated appetite system.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Ilana P. Redmond, Alpana P. Shukla, Louis J. Aronne
Summary: Pharmacological management is effective in treating weight regain after bariatric surgery. Future studies should focus on optimal timing and medication choices for different patient populations.
CURRENT OBESITY REPORTS
(2021)
Article
Pediatrics
Claudia Borzutzky, Eileen King, Claudia K. Fox, William Stratbucker, Jared Tucker, Jennifer K. Yee, Seema Kumar, Suzanne Cuda, Brooke Sweeney, Shelley Kirk
Summary: The survey results show that the majority of paediatric weight management programs offer pharmacotherapy for patients with complications or associated medical conditions, with an increasing trend in usage over time. The study suggests the need for additional robust paediatric drug trials to further guide the use of pharmacotherapy in paediatric weight management.
Article
Nutrition & Dietetics
Chloe Firman, Rachel L. Batterham
Summary: Obesity is a major global health challenge that increases the risk of life-limiting diseases and reduces quality of life. Lifestyle interventions and anti-obesity medications are not sufficient for severely obese individuals, making bariatric surgery the only effective treatment option. Unfortunately, the development of drugs for obesity has been problematic, but scientific advancements in understanding gut hormones have opened up new possibilities for effective and safe treatments.
PROCEEDINGS OF THE NUTRITION SOCIETY
(2022)
Article
Health Care Sciences & Services
Gilly A. Hendrie, Danielle L. Baird, Emily Brindal, Gemma Williams, Jennie Brand-Miller, Beverly Muhlhausler
Summary: This study analyzed data from the CSIRO Total Wellbeing Diet Online program, finding an average weight loss of 2.8 kg, with 43% of stayers losing 5% or more, and an average of 4.9 kg lost. Platform usage was identified as the strongest predictor of weight loss.
JOURNAL OF MEDICAL INTERNET RESEARCH
(2021)
Review
Endocrinology & Metabolism
Richard Song, Brendan J. Nolan, Hecham Harb, Priya Sumithran
Summary: This review evaluated the safety of intensive obesity treatments in people with end-stage kidney disease, finding limited data on very-low-energy diets but highlighting their potential efficacy and the need for close monitoring. Central acting obesity pharmacotherapy and bariatric surgery in this population raised safety concerns, requiring further investigation.
DIABETES OBESITY & METABOLISM
(2021)
Article
Public, Environmental & Occupational Health
Xi Yang, Kaushik Chattopadhyay, Richard Hubbard, Jia-Lin Li, Li Li, Yi Lin
Summary: A 36-month weight management programme in Ningbo, China showed that participants achieved significant initial weight loss at 3 months and maintained the weight loss during 33-month follow-ups. At 36 months, a certain percentage of participants achieved 5%, 10%, and 15% weight loss. The programme is suggested to benefit overweight and obese adults in reducing body weight and maintaining long-term weight loss.
FRONTIERS IN PUBLIC HEALTH
(2021)
Review
Endocrinology & Metabolism
Meetal Mehta, Nawfal W. Istfan, Caroline M. Apovian
Summary: This article reviews the multifaceted personalized treatment approach for obesity, including lifestyle interventions, pharmacotherapy, endoscopic procedures, and surgical procedures. However, current literature lacks large studies on the safety and efficacy of combination therapies involving pharmacotherapy plus surgical procedures.
ENDOCRINE PRACTICE
(2021)
Article
Endocrinology & Metabolism
Emilie Steinbach, Davide Masi, Agnes Ribeiro, Patricia Serradas, Tiphaine Le Roy, Karine Clement
Summary: The study of the gut microbiome is crucial for understanding and treating metabolic diseases. While research on the fecal microbiome has provided valuable insights, relying solely on this may not be enough to draw comprehensive conclusions. The microbiome in the proximal part of the small intestine may play a significant role in metabolic regulation, but further exploration is needed due to limited accessibility.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2024)
Article
Endocrinology & Metabolism
Evangelia Chavdoula, Vollter Anastas, Alessandro La Ferlita, Julian Aldana, Giuseppe Carota, Mariarita Spampinato, Burak Soysal, Ilaria Cosentini, Sameer Parashar, Anuvrat Sircar, Giovanni Nigita, Lalit Sehgal, Michael A. Freitas, Philip N. Tsichlis
Summary: This study reveals the important role of KDM2B in triple-negative breast cancer (TNBC). KDM2B affects cellular resistance to oxidative stress by regulating a network of genes and metabolic enzymes, in collaboration with ATF4 and MYC. Additionally, high expression of KDM2B is associated with poor prognosis in patients.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2024)
Article
Endocrinology & Metabolism
Joongmin Kim, Hyeongsoo Kim, Sang Hyun Park, Yura Kang, Kyungdo Han, Sang-Hak Lee
Summary: This study aimed to investigate the optimal LDL-C level after statin therapy in individuals with intermediate cardiovascular risk. The results showed that achieving LDL-C levels <120 mg/dL after statin therapy could lower the event risk.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2024)
Review
Endocrinology & Metabolism
Ze Chen, Li -Ping Xia, Lang Shen, Dan Xu, Yu Guo, Hui Wang
Summary: Accumulating evidence suggests that NAFLD has an intrauterine origin, with adverse prenatal environments and glucocorticoid exposure playing a crucial role in the developmental programming of fetal hepatic lipid metabolism. The offspring's glucocorticoid-insulin-like growth factor 1 (GC-IGF1) axis is programmed in utero, leading to postnatal catch-up growth and disrupted glucose and lipid metabolism, increasing susceptibility to NAFLD. Mismatch between intrauterine and postnatal environments can further disturb the programmed endocrine axes and accelerate the onset of NAFLD.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2024)
Article
Endocrinology & Metabolism
Fuwen Zuo, Youzhao Wang, Xinlei Xu, Ruihao Ding, Wei Tang, Yu Sun, Xiaojie Wang, Yan Zhang, Jichao Wu, Yusheng Xie, Min Liu, Ziying Wang, Fan Yi
Summary: This study investigates the role of CCDC92 in the pathogenesis of diabetic kidney disease (DKD). The expression of CCDC92 was found to increase in kidney biopsies from patients with DKD and was correlated with glomerular lipid accumulation. Animal studies further confirmed the induction of CCDC92 in the kidney, particularly in podocytes, and the podocyte-specific deletion of Ccdc92 ameliorated podocyte injury and lipid deposition. CCDC92 was shown to promote podocyte lipotoxicity through ABCA1 signaling-mediated lipid homeostasis. Therefore, CCDC92 may serve as a potential biomarker of podocyte injury in DKD and targeting CCDC92 could be an innovative therapeutic strategy for DKD patients.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2024)
Review
Endocrinology & Metabolism
Khanyisani Ziqubu, Phiwayinkosi Dludla, Sihle E. Mabhida, Babalwa U. Jack, Susanne Keipert, Martin Jastroch, Sithandiwe E. Mazibuko-Mbeje
Summary: The discovery and revival of brown adipose tissue (BAT) in adult humans have opened up new possibilities for treating obesity and metabolic diseases. BAT not only plays a role in generating heat, but also secretes signaling molecules known as batokines, which regulate overall metabolism. This review highlights the importance of BAT-derived metabolites in controlling thermogenesis, substrate metabolism, and other biological processes, as well as their potential to alleviate obesity and related metabolic complications.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2024)